IJCRRI Journ Cur Res ReInternational Journal of Current Research and ReviewI Journ Cur Res Re2231-21960975-5241Radiance Research Academy2143HealthcareAN INSIGHT INTO METAL BASED ANTI-CANCER DRUGS KaushalRajKumarNiteshKaushalRajeevAwasthiPamita1523This article is copyright of Popeye Publishing, 20092009This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

Metal complexes play critical role in the treatment of cancer. Cis-platin which is model anticancer drug has been used in the treatment of various types of cancer. But due to its side effects and resistance phenomenon efforts have been made to explore the possibility of synthesizing novel non-platinum based anti-cancer drugs. In addition to platinum based drugs, complexes of other transition metals like titanium, ruthenium, palladium and gold etc. also show pronounced anti-cancer activity. The Complexes with titanium and ruthenium have already been evaluated in phase I and phase II clinical trials. Some transition metal complexes show good anticancer activity against cis-platin resistant cell lines. This review will provide an insight into various platinum as well as non-platinum based anti-cancer drugs.

Transition metal cis-platin Nucleic acid protein platinum titanium ruthenium palladium gold anti-cancer drug amines biological activity.